Clinical Trial Update: BAX 826 Dose-Escalation Safety Study [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation safety study of BAX 826 for Hemophilia A has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 826

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 1 | Status: COMPLETED | Results posted: 2018-09-20